675 articles in this topic
A phase 1 trial shows Temferon — a gene-engineered stem cell therapy — safely delivers interferon-α into glioblastoma tumors with no dose-limiting toxicities.
Combining CD38 and PD-1 inhibitors produced durable remissions in relapsed NK/T-cell lymphoma, with median response duration exceeding 29 months.
A phase 3 trial finds scheduling immunochemotherapy before 3 PM nearly doubles progression-free and overall survival in NSCLC patients.
Ginsenoside Rh4 suppresses colorectal cancer by boosting Akkermansia muciniphila and elevating protective bile acid UDCA via FXR signaling.
Regeneron's bispecific antibody linvoseltamab earns EU approval for relapsed/refractory multiple myeloma after at least three prior therapies.
A CRISPR screen reveals STK40 suppresses anti-tumor immunity in liver cancer — blocking it supercharges immunotherapy response.
A counterintuitive mechanism shows that more NECTIN4 antigen on tumor cells can actually blunt antibody-drug conjugate therapy.
Tumor-infiltrating adipocytes release a lipid metabolite that triggers neutrophil cell death, suppressing CD8+ T cells in pancreatic cancer.
A Nature Medicine study finds pathogenic germline variants in pediatric patients signal elevated cancer risk, reshaping early genetic screening protocols.
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
